$10.98
-2.0%Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
CLYM • NASDAQ
| Climb Bio, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
35.7M | 87.2M | 93.1M | 43.6M | 46.9M | 20.5M | 21.2M | |
65.4M | 63.7M | 13.7M | 80M | 89.6M | 0.0 | 0.0 | |
101.1M | 150.9M | 106.8M | 123.6M | 136.5M | 20.5M | 21.2M | |
0.0 | 1.1M | 2.5M | 6.5M | 6.5M | 0.0 | 0.0 | |
0.0 | 1.1M | 2.5M | 6.5M | 6.5M | 0.0 | 0.0 | |
0.0 | 2.6M | 881K | 1.3M | 4.4M | 1.5M | 25K | |
4.8M | 256K | 112K | 3M | 852K | 11K | 35K | |
105.8M | 154.9M | 110.3M | 134.4M | 148.3M | 22M | 21.3M | |
NON-CURRENT ASSETS | |||||||
793K | 490K | 199K | 471K | 0.0 | 0.0 | 0.0 | |
59.6M | 61.6M | 0.0 | 0.0 | 24.9M | 0.0 | 0.0 | |
1.5M | 215K | 15K | 128K | 70K | 2.6M | 112K | |
61.9M | 62.3M | 214K | 599K | 25M | 2.6M | 112K | |
167.7M | 217.2M | 110.5M | 135M | 173.2M | 24.6M | 21.4M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
2.3M | 705K | 66K | 750K | 1.4M | 1.3M | 711K | |
2.3M | 705K | 66K | 750K | 1.4M | 1.1M | 647K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 207K | 64K | |
1.9M | 4M | 2.3M | 5M | 4.6M | 1.2M | 72K | |
256K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 157K | 334K | 300K | 0.0 | 0.0 | 0.0 | |
2.6M | 31K | 138K | 0.0 | 0.0 | 551K | 0.0 | |
7M | 4.9M | 2.8M | 6.1M | 6M | 3.1M | 783K | |
NON-CURRENT LIABILITIES | |||||||
0.0 | 0.0 | 22K | 0.0 | 7K | 0.0 | 0.0 | |
285K | 375K | 37K | 180K | 7K | 0.0 | 0.0 | |
285K | 532K | 349K | 480K | 0.0 | 0.0 | 0.0 | |
7.3M | 5.3M | 2.9M | 6.3M | 6M | 3.1M | 783K | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 46.6M | 26.2M | |
5K | 7K | 3K | 3K | 3K | 1K | 1K | |
449.8M | 441.7M | 263.6M | 249.9M | 242.9M | 3.2M | 1.9M | |
-289.7M | -229.9M | -156M | -120.9M | -75.6M | -28.1M | -7.5M | |
435K | 23K | -2K | -358K | -123K | 0.0 | 0.0 | |
160.5M | 211.9M | 107.6M | 128.7M | 167.2M | 21.6M | 20.6M | |
160.5M | 211.9M | 107.6M | 128.7M | 167.2M | 21.6M | 20.6M | |
SUMMARY | |||||||
167.7M | 217.2M | 110.5M | 135M | 173.2M | 24.6M | 21.4M | |
125M | 125.3M | 13.7M | 80M | 114.5M | 0.0 | 0.0 | |
541K | 532K | 349K | 480K | 0.0 | 0.0 | 0.0 | |
-35.1M | -86.7M | -92.8M | -43.1M | -46.9M | -20.5M | -21.2M | |
67,764,100 | 67,764,100 | 67,764,100 | 67,764,100 | 67,764,100 | 67,764,100 | 67,764,100 |
CLYM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-3 S-3 N/A | May 29, 2026 | May 29, 2026 | ||
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 03, 2026 | April 01, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 |
Continue your CLYM research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.